{"id":4558,"date":"2025-11-29T06:42:06","date_gmt":"2025-11-29T06:42:06","guid":{"rendered":"https:\/\/academicsolidarity.com\/?p=4558"},"modified":"2025-11-29T06:42:10","modified_gmt":"2025-11-29T06:42:10","slug":"ingiltere-prostat-kanseri-taramasini-onermiyor","status":"publish","type":"post","link":"https:\/\/academicsolidarity.com\/?p=4558&lang=tr","title":{"rendered":"\u0130ngiltere Prostat Kanseri Taramas\u0131n\u0131 \u00d6nermiyor"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Bu hafta Birle\u015fik Krall\u0131k\u2019ta ulusal tarama komitesinin prostat kanseri taramas\u0131n\u0131 genel n\u00fcfus i\u00e7in \u00f6nermeme y\u00f6n\u00fcndeki karar\u0131, uluslararas\u0131 t\u0131p camias\u0131nda yeni bir tart\u0131\u015fma ba\u015flatt\u0131. Karar\u0131n ard\u0131nda tan\u0131d\u0131k bir gerek\u00e7e yer al\u0131yor: PSA (prostat spesifik antijen) testi baz\u0131 hayatlar\u0131 kurtarsa da, gereksiz tan\u0131 ve gereksiz tedavi riskini de beraberinde getiriyor. \u00dcstelik son y\u0131llarda kan\u0131tlar, bu dengenin h\u00e2l\u00e2 hassas oldu\u011funu g\u00f6steriyor (<a href=\"https:\/\/www.ft.com\/content\/9065a8d8-8bfb-40e7-a64d-a326275a00e8\">https:\/\/www.ft.com\/content\/9065a8d8-8bfb-40e7-a64d-a326275a00e8<\/a>).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tarama konusunda en kapsaml\u0131 verilerden biri olan Avrupa\u2019daki ERSPC randomize \u00e7al\u0131\u015fmas\u0131n\u0131n 23 y\u0131ll\u0131k sonu\u00e7lar\u0131 \u015f\u00f6yle: PSA ile d\u00fczenli tarama yap\u0131lan grupta prostat kanserinden \u00f6lme olas\u0131l\u0131\u011f\u0131 g\u00f6reli olarak yakla\u015f\u0131k y\u00fczde 13 daha d\u00fc\u015f\u00fck. Ancak bu \u2018g\u00f6reli\u2019 fark, ger\u00e7ek hayatta \u00e7ok k\u00fc\u00e7\u00fck bir kazanca kar\u015f\u0131l\u0131k geliyor: 23 y\u0131ll\u0131k izlemde, tarama yap\u0131lan her 1.000 erkekten yaln\u0131zca 2 veya 3\u2019\u00fcn\u00fcn prostat kanserinden \u00f6l\u00fcm\u00fc \u00f6nlenmi\u015f g\u00f6r\u00fcn\u00fcyor. Buna kar\u015f\u0131l\u0131k, tarama yap\u0131lan grupta prostat kanseri tan\u0131s\u0131 y\u00fczde 30 oran\u0131nda art\u0131yor; yani bir\u00e7ok erkek, asl\u0131nda hi\u00e7bir zaman sorun yaratmayacak, yava\u015f seyirli bir t\u00fcm\u00f6r i\u00e7in \u201chasta\u201d etiketi al\u0131yor. Bu da gereksiz biyopsiler, gereksiz ameliyatlar ve ya\u015fam kalitesini d\u00fc\u015f\u00fcren komplikasyonlar anlam\u0131na gelebiliyor (<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41160819\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/41160819\/<\/a>). &nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Prostat kanseri taramas\u0131ndaki en \u00f6nemli sorulardan biri, h\u00e2l\u00e2 en temel ara\u00e7lardan olan PSA testinin do\u011frulu\u011fu. PSA\u2019n\u0131n yalanc\u0131 pozitif oran\u0131 olduk\u00e7a y\u00fcksek; \u00f6rne\u011fin PSA\u2019s\u0131 y\u00fcksek bulunan erkeklerin yakla\u015f\u0131k y\u00fczde 70\u2019i biyopsi yap\u0131ld\u0131\u011f\u0131nda kanser \u00e7\u0131km\u0131yor. \u00d6zellikle prostat b\u00fcy\u00fcmesi, enfeksiyonlar ve hatta yak\u0131n zamanda yap\u0131lan cinsel ili\u015fki bile PSA\u2019y\u0131 y\u00fckseltebiliyor. Bu durum, ciddi bir kayg\u0131 y\u00fck\u00fc, gereksiz biyopsiler ve bazen de gereksiz tedavilere uzanan bir zincir anlam\u0131na geliyor. \u00d6te yandan PSA\u2019n\u0131n yalanc\u0131 negatifli\u011fi de g\u00f6z ard\u0131 edilemez; yakla\u015f\u0131k y\u00fczde 15 civar\u0131nda prostat kanseri PSA normal oldu\u011fu h\u00e2lde atlanabiliyor. Bu oran, \u00f6zellikle agresif t\u00fcm\u00f6rlerden duyulan endi\u015feyi canl\u0131 tutuyor (<a href=\"https:\/\/bmjoncology.bmj.com\/content\/2\/1\/e000039\">https:\/\/bmjoncology.bmj.com\/content\/2\/1\/e000039<\/a>).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">G\u00fcncel tart\u0131\u015fmalarda \u00f6ne \u00e7\u0131kan bir di\u011fer konu, tarama yap\u0131lacaksa hangi y\u00f6ntemin tercih edilmesi gerekti\u011fi. Ge\u00e7mi\u015fte prostat kanseri a\u00e7\u0131s\u0131ndan tarama denildi\u011finde, parmakla rektal muayene (DRE) rutin olarak \u00f6neriliyordu. Ancak son y\u0131llarda yap\u0131lan \u00e7al\u0131\u015fmalar, DRE\u2019nin tarama amac\u0131yla kullan\u0131ld\u0131\u011f\u0131nda olduk\u00e7a d\u00fc\u015f\u00fck bir duyarl\u0131l\u0131\u011fa sahip oldu\u011funu g\u00f6sterdi. G\u00fcncel k\u0131lavuzlar\u0131n \u00e7o\u011fu, DRE\u2019nin tarama testinden ziyade, spesifik bir \u015fik\u00e2yeti olan veya PSA\u2019s\u0131 y\u00fcksek \u00e7\u0131kan erkeklerde tamamlay\u0131c\u0131 bir fizik muayene arac\u0131 olarak de\u011ferlendirilmesi gerekti\u011fini vurguluyor. Tarama karar\u0131 al\u0131nacaksa PSA testi, duyarl\u0131l\u0131\u011f\u0131 daha y\u00fcksek oldu\u011fu i\u00e7in tercih edilen y\u00f6ntem. Ancak PSA\u2019n\u0131n da tek ba\u015f\u0131na kesin bir sonu\u00e7 vermedi\u011fi, hem yalanc\u0131 pozitiflik hem de yalanc\u0131 negatiflik riskine sahip oldu\u011fu unutulmamal\u0131.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bug\u00fcn bir\u00e7ok \u00fclke, taramay\u0131 t\u00fcm n\u00fcfusa \u00f6nermek yerine daha se\u00e7ici bir yakla\u015f\u0131m\u0131 benimsiyor. ABD\u2019nin USPSTF \u00f6nerileri, 55\u201369 ya\u015f aras\u0131ndaki erkeklerde taraman\u0131n ancak hekim ve hasta aras\u0131nda kapsaml\u0131 bir g\u00f6r\u00fc\u015fme yap\u0131larak, olas\u0131 yarar ve zararlar\u0131n a\u00e7\u0131k\u00e7a tart\u0131\u015f\u0131lmas\u0131ndan sonra yap\u0131lmas\u0131n\u0131 uygun g\u00f6r\u00fcyor (<a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/prostate-cancer-screening\">https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/prostate-cancer-screening<\/a>). Ya\u015fam beklentisi s\u0131n\u0131rl\u0131 olan veya 70 ya\u015f \u00fcst\u00fc erkeklerde taraman\u0131n zararlar\u0131n\u0131n faydas\u0131ndan fazla oldu\u011funa dikkat \u00e7ekiliyor. \u0130ngiltere\u2019nin son karar\u0131 ise genel taramay\u0131 reddederken, yaln\u0131zca BRCA1\/2 mutasyonu ta\u015f\u0131yan erkeklerde iki y\u0131lda bir taramay\u0131 destekliyor; \u00e7\u00fcnk\u00fc bu grupta prostat kanseri daha erken ve daha agresif seyredebilir. Almanya\u2019da da art\u0131k sistematik \u201crektal muayene + otomatik biyopsi\u201d d\u00f6nemi kapan\u0131yor; Alman k\u0131lavuzu, PSA\u2019ya dayal\u0131, daha \u00f6zelle\u015ftirilmi\u015f (risk, ya\u015f, PSA de\u011feri, talep vb\u2019ye g\u00f6re) bir stratejiyi tavsiye ediyor. Ama bu strateji h\u00e2l\u00e2 \u201cherkese zorunlu\u201d veya \u201ckitle tarama program\u0131\u201d de\u011fil (<a href=\"https:\/\/register.awmf.org\/assets\/guidelines\/043-022OLl_S3_Prostatakarzinom_2025-08.pdf?utm_source=chatgpt.com\">https:\/\/register.awmf.org\/assets\/guidelines\/043-022OLl_S3_Prostatakarzinom_2025-08.pdf<\/a>).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">T\u0131ptaki son geli\u015fmeler ise PSA\u2019ya ek olarak multiparametrik prostat MRI\u2019n\u0131n giderek daha g\u00fc\u00e7l\u00fc bir ara\u00e7 haline geldi\u011fini g\u00f6steriyor. MRI\u2019\u0131n, gereksiz biyopsileri azaltma ve klinik a\u00e7\u0131dan anlaml\u0131 kanserleri daha isabetli yakalama potansiyeli var. Ancak MRI temelli taraman\u0131n toplum genelinde uygulanabilirli\u011fi, maliyet-etkinli\u011fi ve ideal ya\u015f aral\u0131klar\u0131 hen\u00fcz tam olarak netle\u015fmi\u015f de\u011fil (<a href=\"https:\/\/bmjopen.bmj.com\/content\/12\/11\/e059482\">https:\/\/bmjopen.bmj.com\/content\/12\/11\/e059482<\/a>).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">T\u00fcm bu veriler, prostat kanseri taramas\u0131n\u0131n basit bir \u201cyapt\u0131r \/ yapt\u0131rma\u201d karar\u0131 olmad\u0131\u011f\u0131n\u0131 a\u00e7\u0131k\u00e7a ortaya koyuyor. Her erkekte risk profili, ya\u015fam beklentisi, aile \u00f6yk\u00fcs\u00fc ve ki\u015fisel tercihleri farkl\u0131. Hekim ile hasta aras\u0131ndaki iyi bir ileti\u015fim, taraman\u0131n potansiyel faydalar\u0131n\u0131n oldu\u011fu kadar, a\u015f\u0131r\u0131 tan\u0131, a\u015f\u0131r\u0131 tedavi ve test hatalar\u0131n\u0131n do\u011furabilece\u011fi fiziksel ve psikolojik zararlar\u0131n da d\u00fcr\u00fcst\u00e7e konu\u015fulmas\u0131n\u0131 gerektiriyor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sonu\u00e7 olarak, g\u00fcncel kan\u0131tlar genel n\u00fcfusta zorunlu veya otomatik bir taramay\u0131 desteklemiyor. Ancak 50\u201370 ya\u015f aral\u0131\u011f\u0131ndaki sa\u011fl\u0131kl\u0131 erkeklerde, \u00f6zellikle aile \u00f6yk\u00fcs\u00fc olanlarda veya y\u00fcksek riskli gruplarda, tarama se\u00e7ene\u011fi dikkatle de\u011ferlendirilmelidir. Taraman\u0131n tek amac\u0131 erken saptama de\u011fil; ayn\u0131 zamanda erkeklerin kendi sa\u011fl\u0131k kararlar\u0131nda aktif bir rol \u00fcstlenmelerini sa\u011flamak. Hekimlik prati\u011finde ise ama\u00e7, daha \u00e7ok test de\u011fil, daha \u00e7ok bilgilendirme ve daha az zarar. Prostat kanseri taramas\u0131ndaki g\u00fcncel tart\u0131\u015fmalar da bizi tam olarak bu noktaya \u00e7a\u011f\u0131r\u0131yor.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bu hafta Birle\u015fik Krall\u0131k\u2019ta ulusal tarama komitesinin prostat kanseri taramas\u0131n\u0131 genel n\u00fcfus i\u00e7in \u00f6nermeme y\u00f6n\u00fcndeki karar\u0131, uluslararas\u0131 t\u0131p camias\u0131nda yeni bir tart\u0131\u015fma ba\u015flatt\u0131. Karar\u0131n ard\u0131nda tan\u0131d\u0131k bir gerek\u00e7e yer al\u0131yor: PSA (prostat spesifik antijen) testi baz\u0131 hayatlar\u0131 kurtarsa da, gereksiz tan\u0131 ve gereksiz tedavi riskini de beraberinde getiriyor. \u00dcstelik son y\u0131llarda kan\u0131tlar, bu dengenin h\u00e2l\u00e2 [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":4553,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[114],"tags":[],"class_list":["post-4558","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-guncel"],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/academicsolidarity.com\/wp-content\/uploads\/2025\/11\/20251129PSA.jpg?fit=746%2C691&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/academicsolidarity.com\/index.php?rest_route=\/wp\/v2\/posts\/4558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/academicsolidarity.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/academicsolidarity.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/academicsolidarity.com\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/academicsolidarity.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4558"}],"version-history":[{"count":1,"href":"https:\/\/academicsolidarity.com\/index.php?rest_route=\/wp\/v2\/posts\/4558\/revisions"}],"predecessor-version":[{"id":4559,"href":"https:\/\/academicsolidarity.com\/index.php?rest_route=\/wp\/v2\/posts\/4558\/revisions\/4559"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/academicsolidarity.com\/index.php?rest_route=\/wp\/v2\/media\/4553"}],"wp:attachment":[{"href":"https:\/\/academicsolidarity.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/academicsolidarity.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/academicsolidarity.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}